Treating depression in Alzheimer's disease: Integration of differing guidelines

Background: The developments in the understanding of Alzheimer's disease (A D) have led to genetic testing, expansion of research centers, and emergenc e of novel treatment modalities. However, behavioral symptoms and disturban ces remain the leading cause of distress to families and patients. The mana gement of these disturbances is not fully elucidated and not without contro versies. Aim: To review and integrate the two important approaches to manag ement and treatment of depression in AD as published in the American Psychi atric Association's guidelines for the treatment of patients with AD versus the American Academy of Neurology's official publication on managing AD. M ethod: Both publications are analyzed focusing on the pharmacological treat ment of depression. The analysis includes sources of data, generalization, and common and conflicting recommendations. Conclusion: Selective serotonin reuptake inhibitors are the drugs of choice for the treatment of depressio n in AD patients.